Seek Returns

ICLR vs. TEM: ICON vs. Tempus AI Stock Comparison

How do ICON (ICLR) and Tempus AI (TEM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

ICON (ICLR) and Tempus AI (TEM) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

ICON (ICLR) carries decades of public-market history since May 15, 1998, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the ICLR side.

Company profile comparison for ICON (ICLR) and Tempus AI (TEM)
Profile ItemICLRTEM
NameICON plcTempus AI Inc Class A Common Stock
Country/RegionIrelandUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
GICS Sub-IndustryLife Sciences Tools & ServicesLife Sciences Tools & Services
Market Capitalization15.34 billion USD13.87 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 15, 1998June 14, 2024
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ICLR
TEM
GSPC
Loading price history…
ICON (ICLR) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for ICON (ICLR) and Tempus AI (TEM). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for ICON (ICLR) and Tempus AI (TEM). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
Total Return (1Y)30.55%16.25%
Total Return (3Y, Annualized)-6.05%--
Total Return (5Y, Annualized)-5.40%--

Risk Profile

Drawdown History

ICLR
TEM
GSPC
Loading price history…
ICON (ICLR) vs. Tempus AI (TEM), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for ICON (ICLR) and Tempus AI (TEM). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas ICON (ICLR) is closer to market-like at 1.17 — a noticeable difference in market-sensitivity profile.

Risk profile metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
Volatility (1Y, Annualized)68.62%76.08%
Beta (5Y)1.173.34
Max Drawdown (5Y)-76.87%-59.76%
Avg. Volume (3M)943.50K7.20M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ICLR and TEM are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
Sharpe Ratio (1Y)0.380.16
Sortino Ratio (1Y)0.520.26

Profitability

ROE (TTM)

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max
109.18%
Q3
6.23%
ICLR
4.70%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-37.55%

Max
109.18%
Q3
6.23%
Median
-26.66%
TEM
-37.55%
Q1
-64.05%
Min
-167.77%
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max
18.05%
ICLR
5.26%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.54%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
TEM
-12.54%
Min
-17.05%
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile ICON (ICLR) reports 10.73%, ranking against industry peers normally.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max
83.12%
Q3
14.77%
ICLR
10.73%
Median
0.00%
Q1
-78.82%
Min
-207.40%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

-13.82%

Max
83.12%
Q3
14.77%
Median
0.00%
TEM
-13.82%
Q1
-78.82%
Min
-207.40%
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
ROE (TTM)4.70%-37.55%
ROA (TTM)0.85%-7.36%
Net Margin (TTM)5.26%-12.54%
Operating Margin (TTM)10.73%-13.82%
Gross Margin (TTM)23.44%64.46%

Growth

Revenue Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while ICON (ICLR) at 0.76% is closer to the peer norm — faster top-line expansion for TEM.

Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
Revenue Growth (YoY)0.76%83.41%
Revenue Growth (3Y CAGR)2.15%58.29%
EPS Growth (YoY)-71.56%--
EPS Growth (3Y CAGR)-23.82%--

Financial Strength

Current Ratio (MRQ)

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ICLR
1.32
Min
0.10

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.61

Max
25.13
Q3
12.13
Median
5.52
TEM
2.61
Q1
2.47
Min
0.10
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

ICON (ICLR) at 0.38 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
ICLR
0.38
Median
0.15
Q1
0.02
Min
0.00

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.86

TEM
2.86
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
Current Ratio (MRQ)1.322.61
Debt / Equity (MRQ)0.382.86
Net Debt / EBITDA5.55--

Dividends

Dividend Yield (TTM)

Neither ICON (ICLR) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither ICON (ICLR) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

TEM
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max
85.34
ICLR
81.90
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
TEM
--
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): TEM does not report P/E ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
ICLR
1.86
Min
0.01

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.19

Max
58.18
Q3
25.77
TEM
9.19
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile relative to book while Tempus AI (TEM) at 27.66 prices above its industry range — a wide valuation gap against assets.

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
ICLR
1.68
Min
-5.59

TEM

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.66

TEM
27.66
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
ICON (ICLR) vs. Tempus AI (TEM): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for ICON (ICLR) and Tempus AI (TEM)
MetricICLRTEM
P/E Ratio (TTM)81.90--
P/S Ratio (TTM)1.869.19
P/B Ratio (MRQ)1.6827.66
Free Cash Flow Yield (TTM)3.51%0.30%